Grant: CIHR Fellowship
Direct Payment
$120,833.00
Regulation of nonsense-mediated mRNA decay efficiency
EF 2008-09
Résumé
During gene expression DNA is transcribed in to pre-messenger RNA (pre-mRNA) that is modified by a process termed pre-mRNA splicing. The splicing process provides the messenger RNA (mRNA) templates that are translated in to proteins. mRNAs contain signals that mark the beginning and the end (termination codon) of translation. Several quality-control mechanisms have evolved to ensure that information is correctly transferred from genes to proteins. One mechanism is nonsense-mediated mRNA decay (NMD). NMD acts at the mRNA level and targets mRNA harboring premature termination codons (PTCs) for degradation, preventing the generation of potentially toxic proteins. PTCs can result from disease-associated mutations, which without NMD, could have deleterious consequences, even if only one of the two gene copies contains the mutation. Numerous disease-causing mutations introduce PTCs that elicit NMD to different extents. However, what causes a PTC-containing mRNA to elicit efficient or inefficient NMD is unknown. Pre-mRNA splicing is a prerequisite for NMD, and it has been suggested that this may influence NMD efficiency. I propose to identify PTC-containing mRNAs that elicit NMD with different efficiencies, and determine whether mRNAs within each group share splicing-related features. I will elucidate the specific roles of sequence motifs and proteins involved in splicing, in NMD efficiency. The results from the proposed experiments will provide insights into the influence of splicing on NMD efficiency, and help understand the molecular basis of NMD. Recently, a drug in phase-1 clinical trials was shown to promote read-through of PTCs. However this drug can only treat PTCs that do not elicit NMD. The results from the proposed experiments will provide tools to design gene-specific strategies to abrogate NMD, so that all PTC-containing transcripts can be treated with read-through drugs in the context of many genetic diseases with important implications in global health.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
180964
Name
Aznarez Isabel
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Regulation of nonsense-mediated mRNA decay efficiency
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,833
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Nonsense-Mediated Mrna Decay; Pre-Mrna Splicing; Regulation Of Gene Expression; Signal Transduction
Abstract
During gene expression DNA is transcribed in to pre-messenger RNA (pre-mRNA) that is modified by a process termed pre-mRNA splicing. The splicing process provides the messenger RNA (mRNA) templates that are translated in to proteins. mRNAs contain signals that mark the beginning and the end (termination codon) of translation. Several quality-control mechanisms have evolved to ensure that information is correctly transferred from genes to proteins. One mechanism is nonsense-mediated mRNA decay (NMD). NMD acts at the mRNA level and targets mRNA harboring premature termination codons (PTCs) for degradation, preventing the generation of potentially toxic proteins. PTCs can result from disease-associated mutations, which without NMD, could have deleterious consequences, even if only one of the two gene copies contains the mutation. Numerous disease-causing mutations introduce PTCs that elicit NMD to different extents. However, what causes a PTC-containing mRNA to elicit efficient or inefficient NMD is unknown. Pre-mRNA splicing is a prerequisite for NMD, and it has been suggested that this may influence NMD efficiency. I propose to identify PTC-containing mRNAs that elicit NMD with different efficiencies, and determine whether mRNAs within each group share splicing-related features. I will elucidate the specific roles of sequence motifs and proteins involved in splicing, in NMD efficiency. The results from the proposed experiments will provide insights into the influence of splicing on NMD efficiency, and help understand the molecular basis of NMD. Recently, a drug in phase-1 clinical trials was shown to promote read-through of PTCs. However this drug can only treat PTCs that do not elicit NMD. The results from the proposed experiments will provide tools to design gene-specific strategies to abrogate NMD, so that all PTC-containing transcripts can be treated with read-through drugs in the context of many genetic diseases with important implications in global health.
Competitiondate
200902
Approvedterm2
2 yrs 5 mths
Pinamesdelim
Aznarez, Isabel
Approvedterm
2 ans 5 mois
Cihrcontribution2
~ $120,833~ $0~